Issue 10/2004
Content (7 Articles)
An Economic Model of 2-Hour Post-Dose Ciclosporin Monitoring in Renal Transplantation
Paul A. Keown, Bryce Kiberd, Robert Balshaw, Shideh Khorasheh, Carlo Marra, Philip Belitsky, Zoltan Kalo
From Randomised Clinical Trials to Clinical Practice
Samuel Limat, Marie-Christine Woronoff-Lemsi, Céline Menat, Anne Madroszyk-Flandin, Yacine Merrouche
Economic Evaluation of Etoricoxib versus Non-Selective NSAIDs in the Treatment of Osteoarthritis and Rheumatoid Arthritis Patients in the UK
Andrew Moore, Ceri Phillips, Elke Hunsche, James Pellissier, Simone Crespi
Economic Assessment of the Secondary Prevention of Ischaemic Stroke with Dipyridamole plus Aspirin (Aggrenox®/Asasantin®) in France
Jean-Pierre Marissal, Bernard Selke
Warfarin in the Secondary Prevention of Thromboembolism in Atrial Fibrillation
Nicole Mittmann, Paul I. Oh, Scott E. Walker, William R. Bartle
On Cost Effectiveness and Sample Size in Clinical Trials
Augustinus A. M. Hart, Marcel G. W. Dijkgraaf
On Cost Effectiveness and Sample Size in Clinical Trials. The Author’s Reply
Martin E. Backhouse